(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/019878 A2

(51) International Patent Classification[7]: A61K

(21) International Application Number:
PCT/US2003/026937

(22) International Filing Date: 27 August 2003 (27.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/406,517	27 August 2002 (27.08.2002)	US
60/423,754	5 November 2002 (05.11.2002)	US
60/430,001	27 November 2002 (27.11.2002)	US

(71) Applicant *(for all designated States except US)*: **COMPOUND THERAPEUTICS, INC.** [US/US]; 40 Bear Hill Road, Waltham, MA 02451 (US).

(71) Applicant and
(72) Inventor *(for US only)*: **AFEYAN, Noubar, B.** [US/US]; 1 Sunset Ridge, Lexington, MA 02421 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BAYNES, Brian** [US/US]; 125 Josephine Avenue, Apt.1, Somerville, MA 02144 (US). **DASGUPTA, Ruchira** [IN/US]; 143 Rowe Street, Auburndale, MA 02466 (US). **LEE, Frank, D.** [US/US]; 6 Norfolk Road, Chestnut Hill, MA 02467 (US). **WONG, Gordon, G.** [CA/US]; 134 Clinton Road, Brookline, MA 02445 (US).

(74) Agents: **QUISEL, John, D.** et al.; Ropes & Gray LLP, One International Place, Boston, MA 02110-2624 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

[Continued on next page]

(54) Title: ADZYMES AND USES THEREOF



(57) Abstract: Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, *e.g.*, an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer anew specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, *e.g.*, an allergic or inflammatory disease.

WO 2004/019878 A2

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.